Profesionales médicos

Overview

Mayo Clinic medical experts in hypertrophic cardiomyopathy, Jeffrey B. Geske, M.D., Steve R. Ommen, M.D., and Hartzell V. Schaff, M.D., discuss the recent publication of the "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy." They review the top changes to the guideline, including the introduction of a cardiac myosin inhibitor, mavacamten, for support of people with symptomatic obstructive hypertrophic cardiomyopathy (HCM); the evolved guidelines for healthy levels of exercise; the formal split in sudden cardiac death risk assessment between children and adults living with HCM; and new advice on more frequent screening for individuals who have risk factors for atrial fibrillation. For more information, visit Mayo Clinic Medical Professionals – Cardiovascular Diseases.